Use of multiple overlapping sirolimus-eluting stents for treatment of long coronary artery lesions: Results from a single-center registry in 318 consecutive patients

International Journal of Cardiology

Volumn 134, Issue 2, 2009, Pages 231-237

  Ruchin, Peter E ^a   Trabattoni, Daniela ^a   Fabbiocchi, Franco ^a   Montorsi, Piero ^a   Lualdi, Alessandro ^a   Ravagnani, Paolo ^a   Grancini, Luca ^a   Galli, Stefano ^a   Teruzzi, Giovanni ^a   Calligaris, Giuseppe ^a   De Martini, Stefano ^a   Bartorelli, Antonio L ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Coronary artery; Drug eluting stents; Overlapping; Sirolimus

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE; CYPHER; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PACLITAXEL; RAPAMYCIN; TICLOPIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BARE METAL STENT; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; STENT THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGISTRIES; RISK FACTORS; SIROLIMUS;

EID: 64849085105     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.02.012     Document Type: Article

References (34)

1. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. (For the RAVEL study group). N Engl J Med 346 23 (2002) 1773-1780
2. Schofer J., Schluter M., Gershlick A.H., et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double blind, randomised controlled trial (E-SIRIUS). Lancet 362 9390 (2003) 1093-1099
3. Holmes D.R., Leon M.B., Moses J.W., et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109 5 (2004) 634-640
4. Schampaert E., Cohen E.A., Schluter M., et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 43 6 (2004) 1110-1115
5. Rao S.V., Shaw R.E., Brindis R.G., et al. Patterns and outcomes of drug-eluting coronary stent use in clinical practice. Am Heart J 152 2 (2006) 321-326
6. van Domburg R.T., Lemos P.A., Takkenberg J.J., et al. The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease. Eur Heart J 26 7 (2005) 675-681
7. Dibra A., Kastrati A., Mehilli J., et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 7 (2005) 663-670
8. Kastrati A., Mehilli J., Beckerath N., et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. J Am Med Assoc 293 2 (2005) 165-171
9. Sousa J.E., Costa M.A., Abizaid A., et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantiative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 107 1 (2003) 24-27
10. Stankovic G., Cosgrave J., Chieffo A., et al. Impact of sirolimus-eluting and paclitaxel-eluting stents on outcome in patients with diabetes mellitus and stenting in more than one coronary artery. Am J Cardiol 98 3 (2006) 362-366
11. Holmes Jr. D.R., Teirstein P., Satler L., et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. J Am Med Assoc 295 11 (2006) 1264-1273
12. Airoldi F., Rogacka R., Briguori C., et al. Comparison of clinical and angiographic outcome of sirolimus-eluting stent implantation versus cutting balloon angioplasty for coronary in-stent restenosis. Am J Cardiol 94 10 (2004) 1297-1300
13. Kandzari D.E., Roe M.T., Ohman E.M., et al. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol 96 6 (2005) 750-755
14. Chu W.W., Kuchulakanti P.K., Torguson R., et al. Impact of overlapping drug-eluting stents in patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv 67 4 (2006) 595-599
15. Kuchulakanti P.K., Chu W.W., Torguson R., et al. Sirolimus-eluting stents versus paclitaxel-eluting stents in the treatment of coronary artery disease in patients with diabetes mellitus. Am J Cardiol 98 2 (2006) 187-192
16. Lee M.S., Shah A.P., Aragon J., et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 66 4 (2005) 507-511
17. Vermeersch P., and Agostoni P. Should degenerated saphenous vein grafts routinely be sealed with drug-eluting stents?. J Interv Cardiol 18 6 (2005) 467-473
18. Ge L., Iakovou I., Sangiorgi G.M., et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol 45 7 (2005) 989-994
19. Serruys P.W., Lemos P.A., and van Hout B.A. Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the arterial revascularisation therapies study part II (ARTS II). Heart 90 (2004) 995-998
20. Suttorp M.J., Laarman G.J., Rahel B.M., et al. Primary stenting of totally occluded native coronary arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 114 9 (2006) 921-928
21. Tsagalou E., Chieffo A., Iakovou I., et al. Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery. J Am Coll Cardiol 45 10 (2005) 1570-1573
22. Lee C.W., Park K.H., Kim Y.H., et al. Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions. Am J Cardiol 98 7 (2006) 918-922
23. Moreno R., Fernandez C., Hernandez R., et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45 6 (2005) 954-959
24. Camenzind E., Steg P.G., and Wijns W. A meta-analysis of first generation drug eluting stent programs. Presented at the World Congress of Cardiology 2006, Barcelona, September 2-5 (2006)
25. Wenaweser P., Tsuchida K., Vaina S., et al. Late stent thrombosis following drug-eluting stent implantation: data from a large, two-institutional cohort study. Presented at the World Congress of Cardiology 2006, Barcelona, September 2-5 (2006)
26. Vermeersch P., Agostoni P., Verheye S., et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized delayed RRISC trial. J Am Coll Cardiol 50 (2007) 261-267
27. Mehran R., Dangas G., Abizaid A.S., et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 100 18 (1999) 1872-1878
28. Academic Research Council (ARC) of the Food and Drug Administration - Consensus meeting Re: Coronary stent thrombosis 2006.
29. Cutlip D.E., and Kuntz R.E. Cardiac enzyme elevation after successful percutaneous intervention is not an independent predictor of adverse outcomes. Circulation 112 6 (2005) 916-922
30. Bhatt D.L., and Topol E.J. Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation 112 6 (2005) 916-922
31. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 1 (2006) 193-202
32. Finn A.V., Kolodgie F.D., Harnek J., et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112 2 (2005) 270-278
33. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 293 (2005) 2126-2130
34. Chieffo A. Influence of prolonged dual anti-platelet use on late stent thrombosis in a large real-world registry: The Milan/Sieberg/Naples experience. Presentation at the stent thrombosis hot line session (2006), TCT